IPP Bureau
Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
By IPP Bureau - February 01, 2025
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Jubilant Ingrevia commissions new cGMP facility for supplying Niacinamide to global clients
By IPP Bureau - January 31, 2025
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension
By IPP Bureau - January 31, 2025
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Granules strengthens ADHD portfolio with FDA approval for Lisdexamfetamine Dimesylate capsules
By IPP Bureau - January 31, 2025
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Strides reports 14.6% growth in Q3 FY25 revenue
By IPP Bureau - January 31, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Biocon posts Q3 FY25 PAT at Rs. 25 Cr
By IPP Bureau - January 31, 2025
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Biocon’s S&P Global ESG Score improves to 69 for 2024
By IPP Bureau - January 30, 2025
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Piramal Pharma Q3 FY25 revenue up 13%
By IPP Bureau - January 30, 2025
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Roche appoints Wafaa Mamilli as Chief Digital Technology Officer
By IPP Bureau - January 30, 2025
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Enhertu approved in US for breast cancer post more endocrine therapies
By IPP Bureau - January 30, 2025
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Zota Health Care expands Davaindia Network to 1,413 operational stores
By IPP Bureau - January 29, 2025
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
OneSource receives EIR with VAI classification from USFDA for BLD facility
By IPP Bureau - January 29, 2025
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
Syensqo partners with MezLight to launch the world’s first sterile reusable surgical task light
By IPP Bureau - January 29, 2025
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr
By IPP Bureau - January 28, 2025
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr
By IPP Bureau - January 28, 2025
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
